Adenovector
Navigation Links
Adenovector in Medical News
GenVec Announces Second Quarter 2009 Results Conference Call
... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...GenVec Receives Grant for Malaria Vaccine Program
...llaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candidates. Abou..., rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malar......vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or tw...
...ss. To accomplish localized sustained production, Excellarate comprises an adenovector with a gene encoding human platelet-derived growth factor-B (Ad5PDGF-B), in...), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). ...
Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ......vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or tw...
Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ......vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...Adenovector in Medical Technology
GenVec Presents Research on New Ad35 Adenovector at ARVO
GAITHERSBURG, Md.--(BUSINESS WIRE)--May 10, 2007 - GenVec, Inc. (Nasdaq:GNVC) today announced pre-clinical research demonstrating the ability of the Company's new adenovector, Ad35, to induce and sustain protein production in the eye. Lisa L. Wei, Ph.D., GenVec's Director of Pre-Clinical Research, ...TNFerade(TM) Phase III Data Presented at ASCO
... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A......evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or twi...
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
...m preclinical research through ongoing clinical studies using GenVec's core adenovector technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/...ancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malar...
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
...evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or t......evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice...
...evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice...
...of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate, is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice...
Adenovector in Biological Technology
GenVec Reports Second Quarter 2009 Financial Results
... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...... Surg, 2005, May; 87(5): 1059-1068) demonstrated that local delivery of an adenovector encoding BMP-2 (AdBMP-2) in a collagen matrix rapidly induced new bone form... Surg, 2005, May; 87(5): 1059-1068) demonstrated that local delivery of an adenovector encoding BMP-2 (AdBMP-2) in a collagen matrix rapidly induced new bone form...
GenVec Expands Contract Supporting Malaria Vaccine Program
... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A......vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or tw...
Cardium Completes $3.5 Million Credit Facility
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ......vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or t...
Cardium Announces Retirement of Director
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ......vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
Other TagsOther Contentsfrontalfrontalfrontalfrontalfrontalfunnelfunnelfurniturefurniturefurniturefurniturefurunclegalactosegalactosegalactosemiagallium
MARLChk1SLPIOLFM1QUINOLINICMetallophilicMethyltransferaseDILUENTSXPNPEP1LipopolysaccharidepcDNA5LACTOPEROXIDASECRYETTEFRACTALKINE
(Date:11/29/2009)... form between brain cells almost immediately as an...shed this week in Nature . Led by researchers at ...y involved detailed observations of the rewiring p... learning. , The researchers studied mice as the...ed. They observed rapid growth of structures that ...
(Date:11/29/2009)...equals a $41,000 pay raise, researchers say , ...hological therapy may be much more effective at ma...a lottery prize, suggests an English study. , R...o provided information about their mental well-bei... $1,329 course of therapy was so significant that ...
(Date:11/29/2009)...care,s uncertain future and rising costs open the ...dable Acupuncture Scottsdale answers the call. , ...-- Affordable Acupuncture, LLC opened in Scottsdal...h enthusiasm and gratitude. Its increasing popular...ngs, need and cost. "As far as I’m con...
(Date:11/28/2009)...r change after 30-minute psychosocial intervention...hDay News) -- A program that gets persistent drunk...ngerous behavior may lead to significant and long-...new study included 184 men and women with two or m...andomly assigned to one of two interventions. The ...
(Date:11/27/2009)...wire-FirstCall/ -- GSI Group Inc. (Pink Sheets: GS...ology products and semiconductor systems, today an...areholders has been scheduled for Friday, April 30... be announced in due course. As previously announ...m Stephen Bershad, a holder of greater than ten pe...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:GSI Group Calls Shareholders Meeting 2[0] Study shows new brain connections form rapidly during motor learning[0] Psychotherapy Can Boost Happiness More Than Money: Study[0] Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities[1] Drunk Drivers May Respond to Brief Motivational Interview[0] GSI Group Calls Shareholders Meeting
(Date:11/26/2009)...t Staphylococcus Aureus ) and other drug-resistan...ure plasma prototype devices have been developed t...al cocktails. , Two prototype devices have been ...hy skin (e.g. hands and feet) in hospitals and pub...; and another to shoot bacteria-killing agents int...
(Date:11/25/2009)...of the Cell Death Research Laboratory in the Unive...warded the prestigious Johnson & Johnson Focused F...of brain cell damage in Parkinson,s disease. The a...support of innovation and excellence in science, w...lier this month at an event at the Hyatt Regency H...
(Date:11/24/2009)...has been prescribed by traditional healers in Braz... stomach pain to fever and flu. , Now for the fir...been able to scientifically prove the pain relievi... as Brazilian mint. , Testing this ancient South ...Graciela Rocha was able to show that when prepared...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Pharmaxis Announces Placement of 2447 Million and Share Purchase Plan 12459 1Pharmaxis Announces Placement of 2447 Million and Share Purchase Plan 12459 2Orlando Dermatology Aesthetic 26 Clinical 28ODAC 29 Conference Announces Its 2010 Event 47854 1Orlando Dermatology Aesthetic 26 Clinical 28ODAC 29 Conference Announces Its 2010 Event 47854 2Pausing Hormone Therapy Doesnt Cut Mammogram Recalls 47850 1Pausing Hormone Therapy Doesnt Cut Mammogram Recalls 47850 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |